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Available online 4 December 2014Chelidonium majus or greater celandine is spread throughout the world, and it is a very common
and frequent component of modern phytotherapy. Although C. majus contains alkaloids with
remarkable physiological effect, moreover, safety pharmacology properties of this plant are not
widely clarified, medications prepared from this plant are often used internally. In our study the
inhibitory effects of C. majus herb extracts and alkaloids on hERG potassium current as well as on
cardiac action potential were investigated. Our data show that hydroalcoholic extracts of greater
celandine and its alkaloids, especially berberine, chelidonine and sanguinarine have a significant
hERG potassium channel blocking effect. These extracts and alkaloids also prolong the cardiac
action potential in dog ventricular muscle. Therefore these compounds may consequently delay
cardiac repolarization, which may result in the prolongation of the QT interval and increase the
risk of potentially fatal ventricular arrhythmias.
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Chelidoniummajus L. or greater celandine (Papaveraceae) is
spread throughout the world, including Europe, Asia, North-
west Africa and North America. It is an important plant of the
modern phytotherapy, used both externally and internally
either in combination or in monotherapy in the form of
different preparations (tincture, dry and liquid extracts, herbalcognosy, University of
ohmann).tea, gel, ointment, eye-drops). Greater celandine has been used
historically in Europe for the treatment of several diseases,
mainly against bile and liver disorders. Furthermore, its
yellow–orange fresh latex has traditionally been applied for
the treatment of warts and corns, and also for other skin
complaints including tinea infections, eczema and different
tumors of the skin [1]. C. majus derived extracts and purified
compounds exhibit a broad spectrum of biological activities,
such as anti-inflammatory, choleretic, antimicrobial, antiviral,
antitumoral, analgesic, anti-spasmodic and hepatoprotective
effects [2–5]. It is an official drug in the European Pharmacopoeia
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Chinese medicine [2,3].
Phytochemical profile of aerial parts and root of C. majus is
well documented. Over 20 different Chelidonium alkaloidswere
identified. Its main alkaloids are benzylisoquinolines (0.01–1%)
with at least three subgroups: benzophenanthridines
(chelerythrine, chelidonine, isochelidonine, sanguinarine),
protoberberines (berberine, coptisine, dihydrocoptisine,
stylopine) and protopine (protopine) [5].
In general these alkaloids are considered to be the active
principles of the plant [5], since their pharmacological proper-
ties, including antispasmodic, anti-inflammatory, antitumor,
antiviral and antimicrobial activities are well established [1].
However, several studies have demonstrated that berberine
[6–9], chelerythrine [10], chelidonine [11], sanguinarine [11],
and protopine [11] have hERG ion channel activities. Thehuman
ether-à-go-go-related gene (hERG, KCNH2, Kv11.1) encodes a
cardiac voltage-gated potassium channel that provides the
major repolarizing current (rapidly activating delayed rectifier
potassium current, IKr) in phase 3 of the cardiac action potential.
Blockade of the hERG potassium channel may lead to action
potential prolongation at the cellular level, a prolongation of the
QT interval on the electrocardiogramand could enhance the risk
of cardiac arrhythmia and sudden cardiac death. If the hERG
potassium current inhibiting effect of Chelidonium alkaloids is
not counteracted by other constituents of the plant, the internal
use of celandine extracts may increase the risk of potentially
fatal cardiac arrhythmias.
It is also important to note that the alkaloid-mediated
inhibition of the hERG channel may not necessarily lead to the
lengthening of the action potential. Among these alkaloids,
berberine was reported to inhibit hERG potassium current in
transfected HEK cells expressing hERG channels [7–9], to block
delayed rectifier potassium (IKr) current in cardiacmyocytes [6],
and to increase action potential duration on cardiac prepara-
tions [6,7]. Chelerythrine was also described to inhibit hERG
current [10] and prolong action potential [12]. Although
protopine also inhibits the hERG potassium current [11], in
contrast with chelerythrine and berberine it shortens the action
potential duration. This phenomenon is due to themultichannel
effect of protopine, since protopine is not a selective ion channel
antagonist. It acts as a promiscuous inhibitor of other ion
channel currents including L-type Ca2+ (ICa,L) and sodium (INa)
currents [13]. Effects of chelidonine or sanguinarine on cardiac
action potential have not been studied so far.
The aim of the present study was to assess the potential
cardiac risks of internally applied C. majus containing phyto-
therapeutics. Inhibitory effects of greater celandine herb extracts
and alkaloids on hERG potassium current were investigated in
HEK293 (human embryonic kidney) cells stably expressing the
hERG potassium channel with automated patch-clamp system.
Effects of C. majus herb extracts and alkaloids on cardiac action
potential were also investigated in dog ventricular muscle with
conventional microelectrode technique.
2. Materials and methods
2.1. Plant materials
The plant material was originated from a commercial
source. A voucher (No. 824) was deposited in the Institute ofPharmacognosy, University of Szeged. The extracts were
prepared from 5 g grounded herb with 50 ml 25% aqueous
ethanol and 50 ml 45% aqueous ethanol respectively, at room
temperature using ultrasonic bath for 15 min. After filtration,
the solvents were evaporated in vacuum until dryness. For
electrophysiological assays 50 mg of the dried extract
dissolved in 1 ml dimethyl sulfoxide was used. Stock solutions
were stored at−20 °C until use.
2.2. Solvents and chemicals
Berberine chloride, chelerythrine chloride, chelidonine and
sanguinarine nitrate were purchased from Sigma-Aldrich.
Coptisine was isolated from 300 g powdered air dry herbs with
2000ml 2% hydrochloric acid at room temperature. The pHof the
filtered extract was adjusted to 12 with 2% aqueous sodium
hydroxide solution. This step was followed by liquid–liquid
extractionwith 3×700ml chloroform. The further purification of
the concentrated chloroform fractions was performed by prepar-
ative TLC, and on silica using n-propanol–formic acid–water
90:1:9 as eluent affording pure coptisine. The identity and purity
(N98%) of coptisinewere controlled by 1HNMR spectroscopy. For
electrophysiological assay the compounds were dissolved in
DMSO (10 μM stock solution) and stored at−20 °C.
2.3. HPLC–MS apparatus and measurement conditions
Acetonitrile and methanol used for chromatographic anal-
ysis were of HPLC grade and formic acid and ammonia used
for making a buffer solution were of analytical purity. Direct-Q
UV3 clarifier was used to produce purified water for HPLC–MS
measurements.
Chromatographic separation was performed using a
Shimadzu liquid chromatographic system (2 pumps (LC-
20AD); PDA detector (SPD-M20A); autosampler (SIL-20A);
controller (CBM-20A); degasser (DGU-20A3); column thermo-
stat (CTO-20AC)) equipped with a Phenomenex Gemini C18
(100 × 4.60 mm, 5 μm) column. Isocratic elution was applied.
The mobile phase was acetonitrile–methanol–30 mmol
ammonium-formate (pH 3.5) 14.7:18:67.3, respectively. The
flow rate was 0.8 ml/min. The HPLC was coupled to an API 2000
MS/MS with an electrospray (ESI) interface. The source temper-
aturewas 350 °C. Themeasurementswere carried out in positive
ionization mode and the quantification was accomplished by
using multiple reaction monitoring (MRM) with transitions of
m/z 336 → 320 for berberine, 320 → 292 for coptisine,
348→ 322 for chelerythrine, 354→ 275 for chelidonine and
332 → 317 for sanguinarine. Data acquisition and evaluation
were performed using Analyst 1.5.2 software.
Calibration was performed using the standard stock
solution (STD) and one working solution made from the
STD with its dilution. These solutions contained all five
measured analytes dissolved in methanol. The concentrations
of the analytes in the STD were the following: 0.0165 mg/ml
for berberine, 0.0186 mg/ml for coptisine, 0.167 mg/ml for
chelerythrine, 0.0210 mg/ml for chelidonine and 0.0254 mg/ml
for sanguinarine. Different volumes of the standard solutions
were injected and the calibration curvewasmadebyplotting the
peak area of the analyte in function of the injected mass of the
analyte. The correlation coefficients (R2) of the calibration curves
were between 0.9977 and 0.9992.
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from 5.00 g plant material with 50 ml solvents were filtered,
evaporated in vacuum and dissolved in 2.50 ml methanol.
2.4. Automated patch-clamp experiments
The hERG channel current was measured by using planar
patch-clamp technology in the whole-cell configuration with
a 4 channel semi-high-throughput automated patch clamp
system (Patchliner, Nanion Technologies GmbH) [14]. Current
recordings were performed with an EPC-10 Quadro patch-
clamp amplifier (HEKA Elektronik Dr. Schulze GmbH), using
PatchMaster 2.43 software (HEKAElektronikDr. SchulzeGmbH).
The pipetting protocols were controlled by PatchControlHT
1.07.50 software (Nanion Technologies GmbH).
Experiments were carried out at room temperature, on
HEK293 (human embryonic kidney) cells stably expressingFig. 1.MRM spectra (I) and HPLC chromatogram (II) of a STD solution (A: chthe hERG (Kv11.1) potassium channel. The cell line origi-
nated from Cell Culture Service. Cells were maintained at
37 °C, in 5% CO2 in IMDM (PAA Laboratories GmbH) medium
supplemented with 10% FBS (PAA Laboratories GmbH), 2 mM
L-glutamine (Life Technologies Corporation), 1 mMNa-pyruvate
(PAA Laboratories GmbH) and 500 μg/ml G418 (PAA Laborato-
ries GmbH).
Suspension of cells was used for measurements from
running cell culture. Cells were washed twice with PBS (Life
Technologies Corporation) and then detached with trypsin–
EDTA (PAA Laboratories GmbH) for 30–60 s before the
measurement. Trypsin was blocked with MEM (PAA Laborato-
riesGmbH)+10% FBS. The cell suspensionwas next centrifuged
(2 min, 100 g), resuspended in IMDMmedium at a final density
of 1 × 106–5 × 106 cells/ml, and kept in the cell hotel of the
Patchliner. Cells were recovered after 15–30 min and remained
suitable for automated patch clamp recordings for up to 4 h.elidonine, B: coptisine, C: berberine, D: sanguinarine, E: chelerythrine).
Fig. 2.MRM spectra (I) and HPLC chromatogram (II) of the 25% ethanol extract of Chelidoniummajus (A: chelidonine, B: coptisine, C: berberine, D: sanguinarine,
E: chelerythrine).
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recording (compositions in mM): internal solution: KCl 50,
NaCl 10, KF 60, EGTA 20, and HEPES 10, pH 7.2 (KOH); and
external solution: NaCl 140, KCl 4, glucose-monohydrate 5,
MgCl2 1, CaCl2 3, andHEPES 10, pH7.4 (NaOH). Chemicalswere
purchased from Sigma-Aldrich Corporation. All solutions were
sterile filtered. Aliquots were stored at−20 °C andwarmed up
to room temperature before use.
Effects of C. majus extracts and its alkaloids, berberine,
coptisine, chelidonine, and sanguinarine were tested. Stock
solutions were further diluted with external solution, to give
appropriate concentrations for the patch-clamp measure-
ments. The final DMSO concentrations in the tested samples
were 1% or less.
The voltage protocol for hERG ion channel started with a
short−40 mV (100 ms) prepulse step, as a reference. A 20 mVdepolarizing stepwas applied for 3 s, and then the potentialwas
−40mV for 1 s to evoke outward tail current. Holding potential
was−80 mV and pulse frequency was approximately 10 s. The
peak tail current corrected the leak current defined during the
first period to−40 mV.
Recording started in external solution. After this control
period, the increasing concentrations of the test compound
were applied, each for approximately 3 min. 10 μM amitripty-
line was applied as a reference inhibitor then a wash-out step
terminated the protocol.
2.5. Conventional microelectrode technique
All experiments were carried out in compliance with the
Guide for the Care and Use of Laboratory Animals (USA NIH
publication NO 85-23, revised 1996) and conformed to the
Fig. 3.MRM spectra (I) and HPLC chromatogram (II) of the 45% ethanol extract of Chelidoniummajus (A: chelidonine, B: coptisine, C: berberine, D: sanguinarine,
E: chelerythrine).
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cols have been approved by the Ethical Committee for the
Protection of Animals in Research of the University of Szeged,
Szeged, Hungary (approval number: I-74-5-2012) and by the
Department of Animal Health and Food Control of the Ministry
of Agriculture and Rural Development (authority approval
number XIII/1211/2012).
Adult mongrel dogs (8–14 kg) of either sex were used.
Following sedation (xylazine, 1 mg/kg, i.v.) and anesthesia
(thiopental, 30 mg/kg, i.v.), the heart was rapidly removed
through right lateral thoracotomy. The hearts were imme-
diately rinsed in oxygenated modified Locke's solution
containing (in mM): NaCl 120, KCl 4, CaCl2 1, MgCl2 1,
NaHCO3 22, and glucose 11. The pH of this solution was set
between 7.35 and 7.4 when saturated with the mixture of95% O2 and 5% CO2 at 37 °C. Isolated muscle preparations
obtained from the right ventricle were individually mounted
in a tissue chamber with a volume of 50ml. These preparations
were stimulated through a pair of platinum electrodes in
contactwith the preparation using rectangular current pulses of
2 ms duration. These stimuli were delivered at a constant cycle
length of 1000 ms for at least 60 min allowing the preparation
to equilibrate before the measurements were initiated. Trans-
membrane potentials were recorded using conventional glass
microelectrodes, filled with 3 M KCl and having tip resistances
of 5–20 MΩ, connected to the input of a high impedance
electrometer (Experimetria, type 309, Budapest, Hungary)
which was coupled to a dual beam oscilloscope. The resting
potential (RP), action potential amplitude (APA), maximum
upstroke velocity (Vmax) and action potential duration
CA
B
Fig. 4. Concentration-dependent effects of Chelidoniummajus extracts on hERG current. Panels A and B depicted the representative hERG current curves obtained from
cells treatedwith extracts. Empty symbols show the control curves,while full symbols show the effects of 25% ethanol extract (A) and 45% ethanol extract (B) at 5 μg/ml
concentration. Panel C shows the dose–response curves of the 25% ethanol extract and the 45% ethanol extract on hERG current. Estimated IC50 values are 8.30 ±
0.69 μg/ml and 5.09 ± 0.49 μg/ml, respectively (n = 5).
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APD90, respectively) were off-line determined using a
home-made software (APES) running on an IBM compatible
computer equipped with an ADA 3300 analogue-to-digital
data acquisition board (Real Time Devices Inc., State
College, PA, USA) having a maximum sampling frequency
of 40 kHz. The following types of stimulation were applied in
the course of the experiments: stimulation with a constant
cycle length of 1000 ms; and stimulation with different
constant cycle lengths ranging from 300 to 5000 ms.
Attempts were made to maintain the same impalement
throughout each experiment. In case an impalement became
dislodged, adjustment was attempted, and if the action
potential characteristics of the re-established impalement
deviated by less than 5% from the previous measurement,
the experiment continued.
2.6. Statistics
Data are expressed as arithmetic mean ± SEM values.
Results were compared using Student's t-tests for paired data.
Differences were considered significant when P value was less
than 0.05.Table 1
The alkaloid contents of Chelidonium majus extracts.
Chelidonine Coptisine
25% ethanol extract
mg/g 1.7469 6.4194
SEM 4.1569E−03 2.0756E−01
45% ethanol extract
mg/g 3.1935 34.7687
SEM 1.9457E−02 5.7793E−023. Results
3.1. The chemical composition of C. majus extracts
The chemical composition of the extracts was characterized
by RP-HPLC. The main peaks were identified with the aid of on-
line (LC–PDA–MS) spectroscopic data and external standards of
berberine, coptisine, chelerythrine, chelidonine and sanguinarine
(Fig. 1). The berberine, coptisine, chelerythrine, chelidonine and
sanguinarine contents of the dried 25% ethanol extracts were
0.11, 6.42, 0.06, 1.75 and0.22 mg/g, respectively (Fig. 2 and Table
1). The alkaloid contents of the dried 45% ethanol extract were
the following: 0.23, 34.77, 0.13, 3.19 and 0.41 mg/g of berberine,
coptisine, chelerythrine, chelidonine and sanguinarine, respec-
tively (Fig. 3 and Table 1).
3.2. Effects of extracts and alkaloids of C. majus on hERG current
The hERG potassium channel-blocking effects of C. majus
extracts were investigated on HEK293 cells stably expressing
the hERG channel. For this purpose 25% and 45% ethanol (V/V)
extracts were prepared with regard to the Assessment report
EMA/HMPC/369801/2009 on C. majus herb [1], which refersBerberine Sanguinarine Chelerythrine
0.1110 0.2164 0.0612
6.9282E−04 1.2124E−03 5.7735E−05
0.2306 0.4064 0.1253
6.6973E−03 6.9859E−03 3.4641E−04
Table 2
IC50 values of Chelidonium majus extracts and alkaloids on hERG K+ channel.
Sample IC50 ± SEM (μg/ml) IC50 ± SEM (μM)
25% ethanol extract n = 5 8.30 ± 0.69
45% ethanol extract n = 5 5.09 ± 0.49
Berberine n = 5 2.17 ± 0.18 6.46 ± 0.54
Coptisine n = 4 28.86 ± 0.92 90.08 ± 2.88
Chelidonine n = 4 0.35 ± 0.04 1.00 ± 0.10
Sanguinarine n = 5 0.29 ± 0.03 0.88 ± 0.08
162 P. Orvos et al. / Fitoterapia 100 (2015) 156–165these extracts for internal use. Both extracts revealed significant
hERG potassium ion channel inhibitory activity with estimated
IC50 values of 8.30 ± 0.69 μg/ml and 5.09 ± 0.49 μg/ml (Fig. 4
and Table 2).
The hERG blocking potencies of the major alkaloids of the
plant (berberine, chelidonine, coptisine and sanguinarine) were
also evaluated and found that all alkaloids exhibited a substantial
ion channel inhibitory effect apart from coptisine. Chelidonine
and sanguinarine were to have the highest inhibitory effect
with the IC50 values of 1.00 ± 0.10 μM and 0.88 ± 0.08 μM,
respectively, whereas coptisine exhibited only a marginal
effect (IC50= 90.08±2.88 μM). The hERG channelmodulatory
activity of berberine could be characterized by the IC50 value of
6.46 ± 0.54 μM (Fig. 5 and Table 2).3.3. Effects of extracts and alkaloids of C. majus on ventricular
action potential
The effects of C. majus extracts on action potential configu-
ration were studied in canine right ventricular muscle prepara-
tions. The results are shown in Fig. 6. Both extracts moderately
prolonged the action potential duration at 5 μg/ml concen-
tration in a statistically significant manner at a stimulation
cycle length of 1000 ms. The prolongation of APD90 (actionA
B
C
D
Fig. 5. Concentration-dependent inhibitory effects of Chelidonium majus derived alka
obtained from cells treatedwith alkaloids. Empty symbols show the control curves, wh
10 μM berberine (C) and 100 μM coptisine (D). Panel E shows the dose–response cu
effective with IC50 = 0.88 ± 0.08 μM and 1.00 ± 0.10 μM. Berberine IC50 was 6.46 ±
2.88 μM (n= 4–5).potential duration at 90% of repolarization) was 10.5% in
the case of the 25% ethanol extract while the 45% ethanol
extract lengthened the action potential duration with 6.7% at
a stimulation cycle length of 1000 ms. The maximum rate
of depolarization (Vmax) was not influenced significantly
by the extracts. To study the rate-dependent effect of the
extracts on APD90, the preparations were stimulated at cycle
lengths ranging from 300 to 5000 ms. Under these circum-
stances the extracts produced a slight reverse rate-dependent
APD prolongation, especially in the case of 45% extract (Fig. 6
and Table 3).
The effects of berberine, chelidonine and sanguinarine on the
action potential parameters at concentrations of 1 μMand 10 μM
were also investigated in dog ventricular muscle at a stimulation
cycle length of 1000 ms. All drugs showed mild but statistically
significant increase of APD90 (4.6%, 6.1% and 6.3% prolongation,
respectively) at 1 μM concentration. At 10 μM concentration
the action potential lengthening was more remarkable (18.4%,
18.3% and 16.0%). All these compounds prolonged the action
potential duration in a reverse-rate dependent manner (Fig. 7
and Table 3).4. Discussion
In our electrophysiological study we investigated C. majus
herb hydroalcoholic extracts and its four benzylisoquinoline
alkaloids, berberine and coptisine from the protoberberine
subgroup, and chelidonine and sanguinarine from the
benzophenanthridine subgroup using patch-clamp method
and conventional microelectrode technique. 25% and 45%
ethanol extracts were prepared from the herb, because these
extracts have a long tradition of internal application against a
wide scale of different diseases according to the Assessment
report EMA/HMPC/369801/2009 on C.majus herb. Itwas foundE
loids on hERG current. Panels A–D show representative hERG current curves
ile full symbols show the effects of 1 μM sanguinarine (A), 1 μM chelidonine (B),
rves of the examined alkaloids. Sanguinarine and chelidonine were the most
0.54 μM, while coptisine exhibited only a marginal effect with IC50 = 90.08 ±
A B
Fig. 6. Effects of Chelidonium majus extracts (25% ethanol extract and 45% ethanol extract on Panels A and B, respectively) on action potential waveform of dog
ventricular muscle at stimulation cycle length of 1000 ms and rate-dependent effects on action potential duration (APD90).
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prolong the duration of cardiac action potential for the usage
of this herb. The European Medicines Agency published a
public statement on C. majus stating that the benefit–risk
assessment of oral use of the plant is considered negative.
However, the reason for this negative opinion was the high
number of spontaneously reported liver–biliary adverse drug
reactions [15]. The cardiovascular risks of greater celandine
were not considered as a reason for the restriction of therapeutic
application of this plant.Table 3
The electrophysiological effects of Chelidoniummajus extracts in dog ventricular muscle
potential amplitude; Vmax, maximum rate of depolarization; APD90 and APD50, action
n = 5–7.
RP (mV) APA (mV)
Control −85.4 ± 0.5 106.5 ± 2.3
25% ethanol extract 5 μg/ml −85.0 ± 0.8 106.0 ± 2.7
Control −87.3 ± 0.5 106.3 ± 1.8
45% ethanol extract 5 μg/ml −85.8 ± 0.8 104.8 ± 1.2
Control −86.8 ± 1.2 105.4 ± 3.0
Berberine 1 μM −86.1 ± 0.9 107.6 ± 4.0
Control −86.8 ± 1.0 107.3 ± 3.2
Berberine 10 μM −86.1 ± 0.8 107.0 ± 2.5
Control −88.8 ± 3.8 106.8 ± 2.8
Chelidonine 1 μM −85.4 ± 1.4 108.7 ± 3.3
Control −89.0 ± 3.7 106.9 ± 2.7
Chelidonine 10 μM −85.9 ± 1.6 112.9 ± 3.2
Control −89.0 ± 2.1 104.0 ± 2.6
Sanguinarine 1 μM −87.6 ± 2.5 105.5 ± 4.3
Control −86.8 ± 0.9 102.1 ± 3.0
Sanguinarine 10 μM −85.8 ± 1.7 104.3 ± 1.7Many of the alkaloids of greater celandine may be the
reason for cardiovascular risk. Berberine was earlier described
to inhibit hERG potassium current in HEK cells expressing
hERG channels [8], to block IKr current in cardiac myocytes
[6], and to increase action potential duration on cardiac
preparations [6,7], which are well in line with our findings.
Furthermore from this subgroup, we have also studied
coptisine, the main alkaloid of C. majus. Coptisine showed
only a marginal effect on hERG ion channel, therefore its
effect on the action potential was not investigated. These datapreparations at basic cycle length of 1000 ms. RP, resting potential; APA, action
potential durations at 50% and 90% of repolarization. Results are mean ± SEM
Vmax (V/s) APD90 (ms) APD50 (ms)
258.0 ± 39.2 222.4 ± 6.4 178.9 ± 9.2
244.1 ± 39.9 246.5 ± 13.5 200.8 ± 14.9
209.3 ± 25.6 226.0 ± 5.9 179.8 ± 7.2
245.3 ± 22.4 241.3 ± 8.8 186.2 ± 11.5
250.6 ± 46.5 219.4 ± 6.6 181.6 ± 7.3
226.5 ± 44.6 233.1 ± 7.3 196.2 ± 6.6
247.2 ± 39.4 223.1 ± 6.7 183.0 ± 6.4
247.9 ± 20.9 258.4 ± 8.5 215.5 ± 8.3
174.4 ± 18.0 230.4 ± 17.6 180.6 ± 13.6
151.5 ± 9.0 240.1 ± 16.2 189.0 ± 11.4
172.9 ± 18.7 219.6 ± 15.9 174.6 ± 14.0
197.8 ± 36.7 259.7 ± 17.7 204.8 ± 14.1
230.1 ± 43.5 200.4 ± 9.3 156.4 ± 8.5
242.8 ± 59.5 212.9 ± 11.9 170.9 ± 11.4
169.2 ± 23.7 208.0 ± 12.2 172.2 ± 13.0
142.3 ± 24.3 244.2 ± 6.2 202.5 ± 5.7,
A B C
Fig. 7. Effects of Chelidoniummajus alkaloids on action potential waveform of dog ventricular muscle at stimulation cycle length of 1000ms and rate-dependent effects
on action potential duration (APD90). Results of treatment with berberine, chelidonine and sanguinarine are shown on Panels A, B and C, respectively.
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channel. However, berberine prolonged the action potential to
almost the same extent as benzophenanthridines. A potential
explanation to this phenomenon is that berberine also blocks
the slow delayed rectifier potassium channel (IKs) [8] and the
inwardly rectifying potassium current (IK1) [7] during cardiac
action potential repolarization.
The two examined benzophenanthridines, chelidonine and
sanguinarine showed an even stronger inhibitory effect on
hERG channel, having IC50 values ≤1.0 μM, and prolonged the
action potential in a dose-dependent manner. From these
results we can conclude that benzophenanthridines are highly
potent hERG inhibitors (with micromolar or submicromolar
IC50 values).
Interestingly, the third subgroup of benzylisoquinolines,
represented by protopine [13], abbreviates the action potential
duration, suggesting a very complex cardiac action of this herb
with multiple ion channel effects, which are not completely
clear yet.
To assess the significance of the safety concerns related
to the benzylisoquinoline alkaloids of greater celandine, the
alkaloid content of the analyzed extracts was determined.
Remarkable difference was found in the alkaloid content of the
extracts because of the different polarities of the solvents
(Table 1). Coptisine was found to be the major alkaloid of both
the 25% and the 45% ethanol extracts. The chelidonine content
is also considerable, while sanguinarine and berberine are
presented in minor proportions. Chelerythrine was present
only in comparatively lower quantity in either of the two
extracts, thus we have not further studied this alkaloid.
In the present work, to the best of our knowledge, we
report the first experimental evidence of hERG potassium
channel blocking and action potential prolonging effectsof C. majus herb 25% and 45% ethanol extracts. Moreover, the
effect of chelidonine and sanguinarine on the action potential
was investigated for the first time. The examined substances
not only inhibit the hERG current, but also extend the
duration of the action potential. These findings are likely to
contribute significantly to the clarification of the complex
cardiotoxic effects of C. majus.
To estimate the actual risk of the internal usage of C. majus
hydroalcoholic extracts, should know the plasma level of
the alkaloids after oral administration of the herb. Appropiate
cardiac risk estimation of hydroalcoholic extracts of the high
aqueous solubility, poor permeability, and absorption of
berberine result in its low plasma level. It was reported that
the maximum concentration (Cmax) of berberine in the plasma
was 11 ng/ml after a single intragastric administration of
50 mg/kg [16], and 26 ng/ml after a single dose of 200 mg/kg
[17] to rats. In humans, the value of Cmax was only 0.4 ng/ml
after a single oral dose of 400 mg berberine [18], indicating
limited gastrointestinal berberine absorption.
Presently we have rather limited information on the
pharmacokinetic properties of chelidonine and sanguinarine.
The maximum level of sanguinarine in rat plasma after a single
intragastric administration of 10 mg/kg was 192 ng/ml [19].
The Cmax of chelidonine was 5 ng/ml and 41 ng/ml for
sanguinarine in rats after the intragastric administration of
C. majus extract; in this case the doses of the pure alkaloids
were 4 mg/kg and 5.5 mg/kg, respectively [20].
These maximum plasma concentrations seem to be low
and in the case of berberine and chelidonine are several
orders of magnitude smaller than their active concentrations
in this study. Conversely in the case of sanguinarine the
literary Cmax values are much closer to its IC50 on hERG and
its effective concentration on cardiac action potential.
165P. Orvos et al. / Fitoterapia 100 (2015) 156–165Therefore sanguinarine itself due to its relatively high bioavail-
ability may represent some so far not well recognized risk.
Furthermore and even more importantly use of all these
alkaloids may have additive effects further increasing the
possibility of proarrhythmic risk and cardiac sudden death
during administration of drugs effecting the cardiac repolari-
zation or in certain pathophysiological conditions where
repolarization reserve is impaired (including cardiac hypertro-
phy, hypertrophic cardiomyopathy, increased sympathetic
tone, genetic defects, diabetes mellitus, renal failure, hypoka-
lemia, hypothyroidism, etc.) [21,22]. In conclusion, the internal
use of C. majus extracts or its alkaloids, berberine, chelidonine
and especially sanguinarine in some situations where cardiac
repolarization reserve is weak may increase the risk of
potentially fatal ventricular arrhythmias. Our results highlight
the safety concerns regarding the internal use of C. majus:
orally applied greater celandine products need cautious
evaluation from the view of both hepatic and cardiovascular
side effects. With regard to similar hERG blocking activity of
related natural alkaloids [11], further studies are warranted to
evaluate potential hERG-related safety aspects of medicinal
plant extracts and to assess the clinical relevance of these
findings.
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